SCHEMBL6153280

SCHEMBL6153280

NC(=O)c1ccc(NC2CCCN(Cc3ccccc3)CC2)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.55
GAA P10253 2/20 0.52
KCNH2 Q12809 1/20 0.51
KDM4E B2RXH2 1/20 0.49
SCN1A P35498 1/20 0.49
SCN8A Q9UQD0 1/20 0.49
ROCK2 O75116 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
SIGMAR1 Q99720 3/20 0.48
SLC6A12 P48065 2/20 0.48
DRD4 P21917 1/20 0.48
SLC6A13 Q9NSD5 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153502 0.96 OPRK1 (0.59) OPRK1GAAKCNH2KDM4ESCN1A
SCHEMBL6153938 0.92 KAT2B (0.53) OPRK1KCNH2SCN1ASCN8AROCK2
SCHEMBL6157012 0.85 OPRK1 (0.56) OPRK1GAAKCNH2KDM4EMAPT
SCHEMBL6153565 0.84 SIGMAR1 (0.59) OPRK1GAAKCNH2KDM4EALDH1A1
SCHEMBL6156960 0.84 OPRK1 (0.55) OPRK1GAAKCNH2KDM4EALDH1A1
SCHEMBL6154012 0.84 OPRK1 (0.55) OPRK1GAAKCNH2KDM4ELMNA
SCHEMBL6153245 0.84 GAA (0.65) OPRK1GAAKCNH2KDM4EMAPT
SCHEMBL6154433 0.84 LTA4H (0.61) GAAKCNH2ROCK2MAPK1SIGMAR1
SCHEMBL6153689 0.81 MAPK1 (0.55) OPRK1GAAKCNH2KDM4ELMNA
SCHEMBL6819009 0.81 KDM4E (0.61) GAAKDM4ESCN1ASCN8AROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 OPRK1 947/4885GAA 2875/4885KCNH2 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.